Sort
8,912 grants matching “sars cov 2”
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
$802,565Monica Gandhi · University Of California, San Francisco · R01 · FY2022 · AI
Long term adverse health outcomes for women and children following SARS-CoV-2 infection during pregnancy
$802,563Monique Marie Hedderson · Kaiser Foundation Research Institute · R01 · FY2024 · AI
West African Emerging Infectious Disease Research Center (WA-EIDRC)
$801,785Kristian Graugaard Andersen · Scripps Research Institute, The · U01 · FY2023 · AI
Targeting cerebrovascular Wnt/beta-catenin signaling to reverse brain endothelial damage induced by SARS-CoV-2 infection
$801,329Sarah Elizabeth Lutz · University Of Illinois At Chicago · R01 · FY2025 · NS
Longitudinal SARS-CoV-2 mRNA vaccine-induced mucosal, serological, and cellular immunity in children and human milk
$800,605Pia S Pannaraj · Children'S Hospital Of Los Angeles · R01 · FY2022 · AI
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
$800,481Ofer Levy · Boston Children'S Hospital · U19 · FY2021 · AI
Targeted treatment of acute lung injury using isolated lung perfusion
$800,467Irving L Kron · University Of Virginia · R01 · FY2024 · HL
Dissemination and Implementation of COVID-19 Care Innovations in ED Settings
$800,326Peter James Mendel · Rand Corporation · R01 · FY2025 · AI
Adjuvant Comparison and Characterization
$800,000Bali Pulendran · Stanford University · N01 · FY2024 · AI
LARGE SCALE T CELL EPITOPE DISCOVERY - COVID Supplement
$800,000Stephen Wilson · La Jolla Institute For Immunology · N01 · FY2022 · AI
ADJUVANT COMPARISON AND CHARACTERIZATION
$800,000Bali Pulendran · Stanford University · N01 · FY2023 · AI
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** PARTNERSHIP: SARS-COV-2 SURVEILLANCE AND EVOLUTIONARY CHARACTERIZATION IN CAPTIVE AND WILDLIFE ANIMALS
$800,000University Of Illinois · · FY2023 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** THE CAPTIVE CERVID INDUSTRY IS A ROBUST AGRICULTURAL SECTOR WITH NEARLY 10,000 FOR-PROFIT DEER BREEDING OPERATIONS ACROSS NORTH AMERICA, WITH ESPECIALLY HIGH CONCENTRATIONS IN TEXAS. UNEXPECTEDLY, WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS) HAVE EMERGED AS A RESERVOIR FOR SARS-COV-2, THE AGENT OF COVID-19. SEVERAL STUDIES ACROSS THE US AND CANADA HAVE DOCUMENTED DEER TO BE INFECTED WITH MANY DIFFERENT LINEAGES OF THE VIRUS CIRCULATING IN HUMANS. IN FALL 2021, WE REPORTED THE FIRST FINDINGS OF INFECTION AMONG FARMED DEER, IN WHICH OVER 94% OF SAMPLED ANIMALS ON ONE FARM WERE POSITIVE. MANY QUESTIONS REMAIN ABOUT THE VIRAL TRANSMISSION NETWORKS AT DEER FARMS, WHICH MAY INCLUDE SPILLOVER FROM HUMANS OR OTHER ANIMALS AND THREATS OF ONWARD TRANSMISSION AMONGST OTHER ANIMALS. FURTHER, THE IMPACTS OF SARS-COV-2 INFECTIONS ON THE HEALTH OF AGRICULTURAL DEER IS LARGELY UNKNOWN. WE WILL BUILD ON OUR MULTIDISCIPLINARY TEAM'S EXPERIENCE STUDYING COVID-19 PANDEMIC TO UNDERSTAND THE THREAT THAT SARS-COV-2 POSES TO AGRICULTURAL BIOSECURITY SO THAT PLANS CAN BE MADE TO MITIGATE THE RISKS. USING THE LARGE DEER FARM NETWORK IN TEXAS, WE AIM TO QUANTIFY 1) THE FREQUENCY OF CAPTIVE CERVID INFECTION; 2) THE DEGREE OF HORIZONTAL TRANSMISSION AMONG CAPTIVE DEER AND SYMPATRIC LIVESTOCK, WILDLIFE, AND FARM WORKERS; 3) VIRAL GENOME VARIANTS AMONG DEER AND DIRECTIONALITY OF TRANSMISSION AND 4) THE CONSEQUENCE OF SARS-COV-2 INFECTION ON ANIMAL HEALTH. OUR ONGOING PARTNERSHIPS WITH DEER FARMS, ESTABLISHED CAPACITY FOR MOLECULAR AND SEROLOGICAL ASSAYS, AND INTEGRATED TEAM OF EPIDEMIOLOGISTS AND VETERINARIANS WILL FACILITATE THE PROJECT. THIS PROJECT WILL PROVIDE CRITICAL INFORMATION FOR MANAGEMENT DECISIONS FOR IMPROVING AGRICULTURAL BIOSECURITY AND PROTECTING ANIMAL HEALTH.
$799,999Texas A&M Agrilife Research · · FY2023 · National Institute of Food and Agriculture
CEIRR: COVID-19 Research Activities
$799,838Scott Hensley · University Of Pennsylvania · N01 · FY2023 · AI
Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research Center
$799,816Joyce Kimberly Cohen · Emory University · U42 · FY2020 · OD
Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research Center: Husbandry and Management Core
$799,816Joyce Kimberly Cohen · Emory University · U42 · FY2020 · OD
Cincinnati Children's Clinical Center for Targeting the Pathophysiology of Youth-Onset Type 2 Diabetes
$799,578Amy Sanghavi Shah · Cincinnati Childrens Hosp Med Ctr · U01 · FY2024 · DK
Immunogenetics of COVID-19 Immune Response
$799,523Richard B Kennedy · Mayo Clinic Rochester · R01 · FY2025 · AI
Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma
$799,479Stefan Worgall · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · AI
mAbs and vaccines against SARS CoV-2
$799,403Nancy J Sullivan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
$799,372Monica Gandhi · University Of California, San Francisco · R01 · FY2021 · AI
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** WHILE IT HAS BEEN DEMONSTRATED THAT SARS-COV-2 CAN INFECT NUMEROUS DOMESTIC AND WILD ANIMALS, THERE IS A SIGNIFICANT GAP IN OUR UNDERSTANDING OF SARS-COV-2 INFECTIONS IN SMALL AND LARGE WILDLIFE SPECIES, PARTICULARLY AS IT RELATES TO (I) THEIR PERMISSIVENESS, (II) THEIR ABILITY TO BECOME RESERVOIRS FURTHER DRIVING THE EMERGENCE OF NOVEL VARIANTS, (III) SPILLOVER/SPILLBACK POTENTIAL TO OTHER ANIMALS AND HUMANS, AND (IV) VIRULENCE OF EMERGING VARIANTS FROM WILDLIFE. CIRCULATION OF SARS-COV-2 IN WILDLIFE IS OF SIGNIFICANT PUBLIC HEALTH CONCERN, WITH A CRITICAL NEED TO IDENTIFY NEW RESERVOIRS/SUSCEPTIBLE SPECIES AND TO STUDY THE HUMAN-ANIMAL INTERFACE. NATURAL INFECTION AND TRANSMISSION OF SARS-COV-2 AMONG WHITE-TAILED DEER (WTD), THE PREDOMINANT CERVID SPECIES IN NORTH AMERICA, HAS CAUSED A SIGNIFICANT PUBLIC HEALTH CONCERN, PARTICULARLY RELATED TO THE POSSIBILITY OF SPILLBACK TRANSMISSION TO HUMANS; THE LATTER HAS NOW BEEN REPORTED IN ONTARIO, CANADA. THERE IS A SIGNIFICANT GAP IN OUR KNOWLEDGE REGARDING MUTATIONS OCCURRING IN INFECTED DEER AND THEIR ROLE IN VIRAL DYNAMICS, FITNESS, PATHOGENICITY AND TRANSMISSIBILITY IN ANIMAL RESERVOIRS AND AT THE ANIMAL-HUMAN INTERFACE. HENCE, THERE IS A NEED TO BETTER UNDERSTAND HOW SARS-COV-2 BEHAVES AND EVOLVES IN WILDLIFE SPECIES, AND IF THESE COULD REPRESENT POTENTIAL RESERVOIRS IN NATURE. IN THIS PROJECT, WE WILL INVESTIGATE THE PATHOGENICITY, TRANSMISSION AND SPILLOVER POTENTIAL OF DEER-ADAPTED SARS-COV-2 VIRUSES IN CELL CULTURE, ALONG WITH MONITORING INFECTION DYNAMICS IN WILD NORTH AMERICAN RODENTS AND WTD. USING BOTH IN VITRO AND IN VIVO EXPERIMENTS, WE WILL ANALYZE THE EFFECT OF DEER ADAPTATION OF SARS-COV-2 IN ITS ABILITY TO SPILLOVER OR SPILLBACK AND ITS EFFECTIVE TRANSMISSION.THIS PROJECT WILL ENHANCE OUR UNDERSTANDING OF SARS-COV-2 DYNAMICS (INCLUDING SUSCEPTIBILITY, ADAPTABILITY AND TRANSMISSION) IN WILDLIFE SPECIES, THE ANIMAL-HUMAN INTERFACE, AND THE RISK OF SPILLBACK/SPILLOVER, AND, THUS, CARRIES A TRIPARTITE SIGNIFICANCE TO US AGRICULTURE (WTD), WILDLIFE AND HUMAN HEALTH, AND IS A CLEAR FIT WITHIN THE ONE HEALTH CONCEPT. IT IS ANTICIPATED THAT THE FINDINGS FROM THIS WORK WILL BE OF BENEFIT TO SCIENTISTS, ANIMAL HEALTH AUTHORITIES AND POLICYMAKERS, STAKEHOLDERS INCLUDING PRIMARILY DEER HUNTERS AND FARMERS, AND TRAINEES IN SCIENCE INCLUDING GRADUATE STUDENTS AND POSTDOCTORAL SCHOLARS.
$799,371Louisiana State University · · FY2023 · National Institute of Food and Agriculture
Novel diagnostic tools and animal model system for study human/animal interface of COVID-19
$799,280Ying Fang · University Of Illinois At Urbana-Champaign · R01 · FY2021 · AI
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm
$799,024Jeffrey S Glenn · Stanford University · R01 · FY2021 · AI
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
$798,527Monica Gandhi · University Of California, San Francisco · R01 · FY2023 · AI